Seed · Biotech · Lausanne, Switzerland · Founded 2020 · 10–50 employees
Alithea Genomics develops breakthrough RNA sequencing technologies that enable massive sample multiplexing and cost reduction for drug discovery and toxicology applications. Their MERCURIUS DRUG-seq platform can process up to 1,536 RNA samples in a single tube without RNA extraction, dramatically reducing time and costs for pharmaceutical screening. The company raised CHF 6.9M in March 2026 to scale their industrial-grade RNA-seq solutions. Founded as an EPFL spinout in 2020, they've established operations in both Switzerland and the US, positioning themselves as infrastructure providers for AI-driven biomedical research.
No open roles listed right now.